In continuation of the company's announcement dated 7 August 2008 concerning a planned share repurchase programme, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 30 September 2008 owned 22,989,460 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 22,989,460 or 3.63% of the total share capital.
In the second quarter of 2008 a total of 6,525,300 B shares were repurchased, and 107,270 B shares were disposed of to employees in connection with employee incentive programmes.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
For further information please contact:
|
Media: |
Investors: |
|
|
|
|
Elin K Hansen |
Mads Veggerby Lausten |
|
Tel: (+45) 4442 3450 |
Tel: (+45) 4443 7919 |
|
|
|
|
|
Hans Rommer |
|
|
Tel: (+45) 4442 4765 |
|
|
|
|
In North America: |
|
|
Sean Clements |
|
|
Tel: (+1) 609 514 8316 |
|
|
|
Company Announcement no 63 / 2008